"How Patrick Soon-Shiong Made His Fortune Before Buying the

New Post Public Reply Private Reply Replies (0) Message Board
mightycydy
570
" How Patrick Soon-Shiong Made His Fortune Before Buying the L.A. Times "

He is currently Executive Chairman, Global Chief Medical & Technology Officer at ImmunityBio who makes Anktiva, aka Bioshield

https://www.newyorker.com/magazine/2021/11/01...e-la-times

Some interesting excerpts from the above article:

Few figures in modern medicine have inspired as much controversy as Soon-Shiong. “He gets very enthusiastic, and sometimes he might exaggerate,” Hentz said. “He can embellish a little.” Outcomes for his diabetes treatment were disappointing, and one case ended tragically. While pursuing this therapy, he also began researching chemotherapy. At the center of his fortune is a cancer treatment that costs more than a hundred times as much as another drug, available as a generic, that is prescribed for some of the same conditions. Soon-Shiong has been repeatedly accused of financial misrepresentation, self-dealing, price gouging, and fraud. He has been sued by former investors and business partners; he has been sued by other doctors; he has been sued by his own brother, twice; he has been sued by Cher.

My first conversation with Soon-Shiong took place this summer, over Zoom. He was indeed brilliant, charismatic, and enthusiastic, although I wouldn’t call him modest. Our conversations were wide-ranging and at times difficult to follow; he answered my first question with a five-minute monologue on protein interactions, the Large Hadron Collider, climate change, Kobe Bryant’s Achilles tendon, the extinction of the dinosaurs, and the history of the human race. When a concept got technical, he would pull up a digital whiteboard, diagramming networks of cells, proteins, and computers.

By 1993, Soon-Shiong had recruited Steven Craig, his first human patient. Craig had been ravaged by Type 1 diabetes; although he had received a kidney transplant, he was gaunt and walked with a cane, and his eyesight was failing. At the time of his first islet-cell procedure, he was thirty-eight years old and had been unemployed for seven years. Soon-Shiong made a two-inch incision in Craig’s abdomen, then poured in hundreds of thousands of islet cells, taken from cadavers and wrapped in alginic gel. “It was a simple procedure,” Soon-Shiong said. “I wouldn’t even call it surgery.”

Before any long-term results could be determined, Soon-Shiong persuaded Craig to appear at a press conference. A week after the surgery, the “CBS Evening News” showed Craig eating a meal “without insulin, for the first time in thirty years.” Craig’s second procedure, later that year, was covered by the Los Angeles Times. “They’ve done miracles for me,” Craig told the paper.

Other researchers were skeptical. “I had people calling me up saying, ‘Diabetes has been cured!’ ” Scott King, who ran a competing islet-cell startup, said. “But then he’d take Craig to a conference, and people would ask to see clinical data, and Patrick would skillfully parry them.” Craig enjoyed being a star patient. “He got to go to Australia,” his stepson Matthew, who now works as a long-haul trucker, told me. “They seemed to treat him pretty damn well. We all got to stay at Beverly Garland’s hotel.” Soon-Shiong published his results in The Lancet, in 1994, but eventually Craig’s remaining kidney began to fail. The media stopped calling. “He grew depressed after that,” Craig’s ex-wife, Melodie, said. “He liked the attention.” In 1998, Craig checked into a hotel in Orange County and shot himself in the head.

Craig’s family told me that they did not blame Soon-Shiong for the suicide. “We understand that sometimes medical practices go wrong,” Matthew said. “That’s how they find out shit.” But Soon-Shiong’s promotional tactics may have damaged his reputation as a physician. He was publicly chastised by the head of the American Diabetes Association. “He told the world he was curing diabetes,” Michael Zinner, the former chief of surgery at U.C.L.A., told Forbes in 2003. “But, in the scientific realm, you need to have your results reproduced by others to have them validated.”

Soon-Shiong has labelled his approach to cancer “quantum oncotherapeutics,” although it does not rely on findings from quantum physics. He has a tendency to make his therapies sound more innovative than they are. When I asked him about Kobe Bryant’s Achilles-tendon surgery, he said, “The treatment for Achilles rupture is completely wrong. I asked Kobe if he wanted to dunk again, and he said yes. So we went completely against the doctor’s orders, and Kobe has his treatment, and he dunked again.” ElAttrache, who performed the surgery, told me, “That this was some sort of novel thing that no one else had considered, you know, I just, I don’t know . . . I think that’s a little bit of an overstatement.”

Soon-Shiong likes to present himself as an intellectual iconoclast, fighting a lonely war against the establishment. In reality, he has operated inside the boundaries of mainstream medical research, even in the islet-cell days. “At the time, I found this kind of self-promotion unethical,” Scott King said. “But I will say, now that I’m older, I realize you need someone like that on your side. He was good at raising money.”

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Poland's Economic Boom: A Case for Freedom and Growth

Updated Category News Views 74

Poland's Remarkable Journey to Economic Power Freedom, they say, fuels progress—and Poland stands as a pulsating testament to that very idea. Thirty-odd years ago, shedding the chains of Soviet-imposed communism, Poland was all systems go, taking the wheel of its own destiny. For the first time, Polish innovation and industry were unleashed, paving the road toward...

Continue Reading
Bramshill Fund Takes Top Spot in 2026 Fund Awards

Updated Category News Views 32

Another Feather in Bramshill's Cap They've done it again, folks. The Bramshill Multi-Strategy Income Fund has just snagged the 40 Act Fund of the Year award at the 2026 Hedge Fund Performance Awards. This ain't just another plaque for the wall; it's a nod to some serious heavy lifting by the folks handling this beast of a portfolio. The award, dished out by With...

Continue Reading
Sino Biological Boosts AI Protein Discovery Efficiency

Updated Category News Views 37

Dissecting the Bridge Between AI and Biology In the cutthroat world of biotech, every second counts. Sino Biological is taking a good hard look at bridging AI and practical applications with their shiny new 4RISE™ solution. The stakes couldn't be higher—turning computer-generated protein ideas into lab-tested realities is no small feat. And believe me, researchers...

Continue Reading
Full Sail's Reach Expands with Film School Honor

Updated Category News Views 39

Full Sail's Cinematic Spotlight Moment Alright, folks, you're hearing it right: Full Sail University's caught the spotlight in TheWrap Magazine's annual who's-who of film schools for 2026. That's a pat on the back any educational institution would kill for, highlighting that Full Sail is playing with the big boys when it comes to film education. Beyond Classic Classroom...

Continue Reading
Alyssa Bunch: Big Moves in Tennessee Real Estate

Updated Category News Views 104

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...

Continue Reading
RLX Technology Gears Up for Q3 Earnings Call Ahead

Updated Category News Views 150

Under the Microscope: RLX Q3 2026 Earnings Get ready, because November 20 is shaping up to be a real event for RLX Technology watchers. The e-vapor heavyweight is gonna drop its Q3 results right before the crack of dawn U.S. markets open. Now, that's a time that stirs more coffee pots than debates—at 7:00 AM Eastern Time, to be precise. So, you better be braced for some...

Continue Reading
GCC's Path to 10 Gbps: U6GHz Revolution Unfolds

Updated Category News Views 96

On the Journey to 10 Giga: The U6GHz Leap You know, sometimes the telco world kicks up a fuss about speed, and this time, it’s the upper 6 GHz (or U6GHz) band that’s got everyone abuzz. At the Telecom Review Leaders' Summit in Dubai, industry bigwigs gathered to discuss how this spectrum could catapult the GCC into the 10 Gbps connectivity stratosphere. Fancy-talk...

Continue Reading
DentScribe Smashes AI Perio Chart Test with Perfect Score

Updated Category News Views 95

High Stakes in Dental Tech: DentScribe's Impeccable Show The dental tech world just got a jolt, and it's not from your morning coffee. DentScribe, the brains cooking up some AI magic in Sunnyvale, has unleashed a real heavyweight. They dropped the mic on their Periodontal Charting Benchmark 1.0 by acing 68 out of 68 tests without breaking a sweat—literal perfection in...

Continue Reading
Suiteify Teams Up With Findity for German Launch

Updated Category News Views 85

Striking a Partnership That Makes Sense Today's deal rolls in like thunder on a quiet afternoon. Suiteify, the master of HR and business software in the DACH region, hooks up with Findity to unleash a new game-changer in Germany. They’re cooking up Suiteify Expense & Travel, and if you're in the mid-sized business space, it’s worth a pause to see how these two horses...

Continue Reading
2026 Chinese Congress to Advance Integrative Oncology

Updated Category News Views 98

Changsha Set to Host a Global Convergence in Oncology For those interested in the blend of age-old wisdom and cutting-edge science, it’s time to tune into what’s happening in Changsha, China. The 2026 Chinese Congress on Holistic Integrative Oncology is about to kick off from November 12 to 15, and it's got quite the lineup of star-studded brainpower in the oncology...

Continue Reading

Top 5 Most Recently Viewed Articles

Bon Secours Mercy Health Collaborates on New Cardiac Facility

Updated Category News Views 156

A New Era in Cardiovascular Care In an exciting development for cardiovascular health services, Bon Secours Mercy Health, AlignedCardio, and Compass Surgical Partners have joined forces to establish a cutting-edge cardiovascular surgery center. This center, named the Short Pump Cardiovascular Ambulatory Surgery Center, is slated to open its doors in late 2025. The new...

Continue Reading
Fluence Energy Faces Investigation Over Securities Issues

Updated Category News Views 217

Fluence Energy Under Scrutiny for Potential Securities Fraud Pomerantz LLP is proactively investigating claims on behalf of investors linked to Fluence Energy, Inc. (NASDAQ: FLNC). This investigation aims to determine whether Fluence, along with its officers and directors, have participated in any unlawful business practices or securities fraud that could affect its...

Continue Reading
Oramed Pharmaceuticals Enters $11.5 Million Clinical Trial Deal

Updated Category News Views 243

Oramed Pharmaceuticals Inc. (NASDAQ: ORM) landed a key deal back in 2024 with InClin, Inc., a clinical research outfit that could shift the gears on their clinical trials. This agreement is meant to fuel Oramed's Phase 3 clinical trial efforts, as detailed in their filing. The stakes are high here; we’re talking about an oral insulin capsule aimed at type 2...

Continue Reading
Charles El-Moussa Joins MRED as General Counsel

Updated Category News Views 122

Charles El-Moussa Joins MRED as General Counsel Midwest Real Estate Data (MRED) has officially announced that Charles El-Moussa is stepping in as the company’s new General Counsel, effective immediately. A Strategic Move for MRED El-Moussa's appointment is a significant and strategic step for MRED. He will play a crucial role in providing legal guidance as the company...

Continue Reading
Caristo Diagnostics Celebrates Recognition for Cardiac Technology

Updated Category News Views 75

Caristo Diagnostics Triumphs in Digital Health Awards Caristo Diagnostics, a pioneering entity in the field of cardiovascular disease diagnostics and risk prediction, has recently celebrated a significant achievement. The company was awarded the prestigious Digital Health Hub Foundation's Digital Health Awards, where it was acknowledged as a 'Rising Star' in the Provider...

Continue Reading